CTLA4 and neoplasm: As summarized in a recent review addressing the immune checkpoint inhibitors in Tregs, these cells constitutively express immune checkpoints like CTLA-4 but also PD-1, BTLA, LAG-3, and TIM-3, and upregulate inhibitory receptors during activation and at tumor sites (1).